StreetInsider.com News Articles

Nurix (NRIX) PT Raised to $31 at UBS

Wed, 22 Jul 2026 07:16:50 -0400

UBS analyst David Dai raised the price target on Nurix (NASDAQ: NRIX) to $31.00 (from $23.00) while maintaining a Buy rating.

Nurix closes Roche collaboration deal for BTK degrader drug

Tue, 21 Jul 2026 16:01:49 -0400

Nurix Therapeutics (NASDAQ: NRIX) announced the closing of its global collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg, following clearance under the Hart-Scott-Rodino Antitrust Improvements Act.

Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is eligible to receive development, regulatory, and sales milestones totaling up to $2.3 billion. Development costs will be shared, with Nurix covering 40% and Roche covering 60%. Profits and losses from U.S. commercialization will be split equally between the two companies.

Outside the United States, Roche will be solely responsible for commercialization, with Nurix eligible to receive royalties

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunolo

Tue, 21 Jul 2026 16:01:00 -0400

BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the closing of its previously announced global collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg, following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Summary of Business Terms
Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is eligible to receive development, regulatory and sales milestones for potential total payments of up to

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunolo

Tue, 21 Jul 2026 16:01:00 -0400

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunolo

Tue, 21 Jul 2026 16:01:00 -0400

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunolo

Tue, 21 Jul 2026 16:01:00 -0400

Nurix (NRIX) PT Raised to $34 at Mizuho

Mon, 13 Jul 2026 06:44:51 -0400

(Updated - July 13, 2026 6:44 AM EDT)

Mizuho analyst Joseph Catanzaro raised the price target on Nurix (NASDAQ: NRIX) to $34.00 (from $30.00) while maintaining a Outperform rating.

The analyst commented: "Following the announcement of the transformative deal with Roche for bexdeg, NRIX reported 2Q26 EPS and provided a pipeline update. Overall, guidance around pipeline milestones are unchanged, with expectations in 2H26 we'll see more Phase Ib data for bexdeg in CLL/NHL, the Phase III 2L+ CLL will dose its first patient and the SNY-partnered STAT6 degrader will move into a Phase I study. Again, we see the Roche/bexdeg collaboration as

Nurix (NRIX) PT Raised to $34 at Mizuho

Mon, 13 Jul 2026 06:44:51 -0400

(Updated - July 13, 2026 6:44 AM EDT)

Mizuho analyst Joseph Catanzaro raised the price target on Nurix (NASDAQ: NRIX) to $34.00 (from $30.00) while maintaining a Outperform rating.

Nurix (NRIX) PT Raised to $34 at Mizuho

Fri, 10 Jul 2026 12:49:13 -0400

(Updated - July 10, 2026 12:49 PM EDT)

Mizuho analyst Joseph Catanzaro raised the price target on Nurix (NASDAQ: NRIX) to $34.00 (from $30.00) while maintaining a Outperform rating.

The analyst commented: "Following the announcement of the transformative deal with Roche for bexdeg (note here), NRIX reported 2Q26 EPS and provided a pipeline update. Overall, guidance around pipeline milestones are unchanged, with expectations in 2H26 we'll see more Phase Ib data for bexdeg in CLL/NHL, the Phase III 2L+ CLL will dose its first patient and the SNY-partnered STAT6 degrader will move into a Phase I study. Again, we see the Roche/bexdeg

Nurix (NRIX) PT Raised to $34 at Mizuho

Fri, 10 Jul 2026 12:49:13 -0400

(Updated - July 10, 2026 12:49 PM EDT)

Mizuho analyst Joseph Catanzaro raised the price target on Nurix (NASDAQ: NRIX) to $34.00 (from $30.00) while maintaining a Outperform rating.

Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'

Fri, 10 Jul 2026 12:08:24 -0400

Baird analyst Brian Skorney reiterated an Outperform rating and $33.00 price target on Nurix (NASDAQ: NRIX).

The analyst comments "No change to outlook on earnings. Following the impactful Roche deal announcement, the 2Q print was largely straightforward, with EPS largely in line with our expectations. We continue to think the additional support from Roche in creating opportunity to expand the R&D effort further into immunology, with the oncology update at EHA continuing to look promising, sets the stage for a favorable breadth of opportunity supporting upside potential on the name."

For an analyst ratings summary and ratings history on Nurix click

Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'

Fri, 10 Jul 2026 12:08:24 -0400

Baird analyst Brian Skorney reiterated an Outperform rating and $33.00 price target on Nurix (NASDAQ: NRIX).

For an analyst ratings summary and ratings history on Nurix click

Nurix (NRIX) PT Raised at Truist Securities; 'Roche Partnership Broadens Path to Value Creation'

Fri, 10 Jul 2026 09:08:26 -0400

(Updated - July 10, 2026 9:08 AM EDT)

Truist Securities analyst Greg Renza raised the price target on Nurix (NASDAQ: NRIX) to $34.00 (from $32.00) while maintaining a Buy rating.

The analyst commented: "Roche Partnership Broadens Path to Value Creation; NRIX's 2Q26 EPS and our follow-up call with mgmt were focused on the recent Roche partnership, which in our view, further broadens the path to value creation. In CLL, mgmt highlighted greater flexibility to explore bexdeg combos in earlier lines besides the ongoing pivotal CLL-201 (triple-exposed) and planned ph.III CLL-306 (2L+; mid-2026 start). Beyond oncology, I&I development continues to advance with ph.II

Nurix (NRIX) PT Raised at Truist Securities; 'Roche Partnership Broadens Path to Value Creation'

Fri, 10 Jul 2026 09:08:26 -0400

(Updated - July 10, 2026 9:08 AM EDT)

Truist Securities analyst Greg Renza raised the price target on Nurix (NASDAQ: NRIX) to $34.00 (from $32.00) while maintaining a Buy rating.

Nurix (NRIX) PT Raised to $33 at RBC Capital; 'I&I Opportunities Remain Underappreciated'

Fri, 10 Jul 2026 08:43:40 -0400

(Updated - July 10, 2026 8:43 AM EDT)

RBC Capital analyst Brian Abrahams raised the price target on Nurix (NASDAQ: NRIX) to $33.00 (from $30.00) while maintaining an Outperform rating.

The analyst commented: "Bex-deg Partnership Impact, CLL Promise, and I&I Opportunities Remain Underappreciated; Coming off the large Roche deal, we believe NRIX is well positioned, with a strengthened balance sheet and strong partner to defray costs and expand bex-deg's LT opportunity, and with bex-deg CLL data continuing to evolve favorably. I&I opportunities continue to have potential based on early data - and appreciation for these should grow with IRAK4 ph.I data this

Nurix (NRIX) PT Raised to $33 at RBC Capital; 'I&I Opportunities Remain Underappreciated'

Fri, 10 Jul 2026 08:43:40 -0400

(Updated - July 10, 2026 8:43 AM EDT)

RBC Capital analyst Brian Abrahams raised the price target on Nurix (NASDAQ: NRIX) to $33.00 (from $30.00) while maintaining an Outperform rating.

Nurix (NRIX) PT Raised to $40 at Stifel

Fri, 10 Jul 2026 07:38:06 -0400

Stifel analyst Stephen Willey raised the price target on Nurix (NASDAQ: NRIX) to $40.00 (from $34.00) while maintaining a Buy rating.

Nurix (NRIX) PT Raised to $34 at H.C. Wainwright

Fri, 10 Jul 2026 06:53:10 -0400

(Updated - July 10, 2026 6:53 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on Nurix (NASDAQ: NRIX) to $34.00 (from $32.00) while maintaining a Buy rating.

The analyst commented: "For F2Q26, Nurix recorded a net loss of $0.81 per share—wider than our previously estimated net loss of $0.72 per share—with $9.0M generated in collaboration revenue vs. our previously estimated $15M. R&D and SG&A expenses were $87.7M and $15.6M, respectively, vs. our estimates of $85.8M and $14.8M. After accounting for the upfront payment from Roche, which is expected in F3Q26, Nurix has approximately $1.14B in pro forma cash on

Nurix (NRIX) PT Raised to $34 at H.C. Wainwright

Fri, 10 Jul 2026 06:53:10 -0400

(Updated - July 10, 2026 6:53 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on Nurix (NASDAQ: NRIX) to $34.00 (from $32.00) while maintaining a Buy rating.

Form 10-Q Nurix Therapeutics, Inc. For: May 31

Thu, 09 Jul 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260709/26753328.html

Form 10-Q Nurix Therapeutics, Inc. For: May 31

Thu, 09 Jul 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260709/26753328.html

Form 8-K Nurix Therapeutics, Inc. For: Jul 09

Thu, 09 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260709/26753302.html

Form 8-K Nurix Therapeutics, Inc. For: Jul 09

Thu, 09 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260709/26753302.html

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 09 Jul 2026 16:01:00 -0400

Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment

Co-development, co-commercialization collaboration includes comprehensive clinical development plan in malignant hematology and enables expansion of bexobrutideg into chronic spontaneous urticaria (CSU) and multiple sclerosis (MS)

Presented clinical data update at the European Hematology Association (EHA) supporting bexobrutideg's potential as a best-in-class BTK degrader across multiple lines of therapy in CLL

Well capitalized with cash, cash equivalents and marketable securities of $443.5 million as of May 31, 2026, and pro-forma cash of approximately

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 09 Jul 2026 16:01:00 -0400

Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment

Co-development, co-commercialization collaboration includes comprehensive clinical development plan in malignant hematology and enables expansion of bexobrutideg into chronic spontaneous urticaria (CSU) and multiple sclerosis (MS)

Presented clinical data update at the European Hematology Association (EHA) supporting bexobrutideg's potential as a best-in-class BTK degrader across multiple lines of therapy in CLL

Well capitalized with cash, cash equivalents and marketable securities of $443.5 million as of May 31, 2026, and pro-forma cash of approximately